Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. (Q34613492)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

2 references

14 September 2020

Anti-tumour activity of bisphosphonates in preclinical models of breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

14 September 2020

experimental mammary neoplasms

1 reference

19 September 2019

1 reference

12 November 2019

1 reference

14 September 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Robert E Coleman

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

16 December 2010

8 references

13 March 2019

3 April 2019

20 June 2019

17 June 2019

19 September 2019

12 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

14 September 2020

Breast Cancer Research

8 references

13 March 2019

3 April 2019

20 June 2019

17 June 2019

19 September 2019

12 November 2019

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

14 September 2020

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial

18 January 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Osteonecrosis of the jaw in a patient on Denosumab

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Anti-tumour effects of bisphosphonates--what have we learned from in vivo models?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Activation of γδ T cells by bisphosphonates.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Expression profile and synthesis of different collagen types I, II, III, and V of human gingival fibroblasts, osteoblasts, and SaOS-2 cells after bisphosphonate treatment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Tumor-associated macrophages: effectors of angiogenesis and tumor progression.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Multiphoton microscopy and fluorescence lifetime imaging microscopy (FLIM) to monitor metastasis and the tumor microenvironment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Antitumoral and antiangiogenic efficacy of bisphosphonates in vitro and in a murine RENCA model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Alendronate decreases orthotopic PC-3 prostate tumor growth and metastasis to prostate-draining lymph nodes in nude mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Molecular mechanisms of action of bisphosphonates: current status.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Mechanisms of disease: Preclinical reports of antineoplastic synergistic action of bisphosphonates

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

From genetic abnormality to metastases: murine models of breast cancer and their use in the development of anticancer therapies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Metastasis to bone: causes, consequences and therapeutic opportunities

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Preclinical studies with zoledronic acid and other bisphosphonates: impact on the bone microenvironment

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Bisphosphonates: a review of their pharmacokinetic properties

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases

7 July 2018

1 reference

Biodistribution and plasma protein binding of zoledronic acid

21 January 2018

1 reference

Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid

21 January 2018

1 reference

Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells.

21 January 2018

1 reference

Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel?

21 January 2018

1 reference

Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation

21 January 2018

1 reference

Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study

21 January 2018

1 reference

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.

21 January 2018

1 reference

Tumor-associated macrophages press the angiogenic switch in breast cancer

21 January 2018

1 reference

Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer.

21 January 2018

1 reference

Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.

21 January 2018

1 reference

Site-specific human breast cancer (MDA-MB-231) metastases in nude rats: model characterisation and in vivo effects of ibandronate on tumour growth.

21 January 2018

1 reference

Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer

21 January 2018

1 reference

Synergistic effect of bisphosphonate and docetaxel on the growth of bone metastasis in an animal model of established metastatic bone disease

21 January 2018

1 reference

Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study.

21 January 2018

1 reference

In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3046431

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

26 October 2018

1 reference

Zoledronic acid-induced IPP/ApppI production in vivo

21 January 2018

1 reference

12 December 2020

Use of bisphosphonates and risk of postmenopausal breast cancer

1 reference

12 December 2020

Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro

1 reference

12 December 2020

Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma

1 reference

12 December 2020

Gamma/delta T-cell stimulation by pamidronate

1 reference

12 December 2020

Identifiers

DOI

10.1186/BCR2769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

18 January 2020

1012736800

0 references

Fatcat ID

release_fmjrlixrffaa7jebqnt2yaoo3u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/fmjrlixrffaa7jebqnt2yaoo3u

24 November 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21176176%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

PubMed publication ID

21176176

1 reference